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Abstract
Background:  Cancer development is accompanied by genetic phenomena like deletion and
amplification of chromosome parts or alterations of chromatin structure. It is expected that these
mechanisms have a strong effect on regional gene expression.
Results:  We investigated genome-wide gene expression in colorectal carcinoma (CRC) and
normal epithelial tissues from 25 patients using oligonucleotide arrays. This allowed us to identify
81 distinct chromosomal islands with aberrant gene expression. Of these, 38 islands show a gain in
expression and 43 a loss of expression. In total, 7.892 genes (25.3% of all human genes) are located
in aberrantly expressed islands. Many chromosomal regions that are linked to hereditary colorectal
cancer show deregulated expression. Also, many known tumor genes localize to chromosomal
islands of misregulated expression in CRC.
Conclusion: An extensive comparison with published CGH data suggests that chromosomal
regions known for frequent deletions in colon cancer tend to show reduced expression. In
contrast, regions that are often amplified in colorectal tumors exhibit heterogeneous expression
patterns: even show a decrease of mRNA expression. Because for several islands of deregulated
expression chromosomal aberrations have never been observed, we speculate that additional
mechanisms (like abnormal states of regional chromatin) also have a substantial impact on the
formation of co-expression islands in colorectal carcinoma.
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Background
DNA microarrays have become a standard tool for the
analysis of mRNA expression levels in colorectal cancer
cells. Most studies focus on the identification of differen-
tially expressed genes in tissues at different tumor stages
or on the identification of new tumor subclasses and their
diagnostic gene expression signatures [1-6]. In contrast,
much less is known about the influence of chromosomal
neighborhood on gene expression in tumors.
In tumors different genetic mechanisms are known to
affect gene expression in wider chromosomal regions.
Chromosomal aberrations, like homozygous and hetero-
zygous deletions or amplifications, alter the DNA copy
number of large genomic regions or even whole chromo-
some arms, leading to inactivation of tumor suppressor
genes [7,8] or to activation of oncogenes. Another genetic
phenomenon that is assumed to have drastic effects on
gene expression in cancer cells is the aberrant alteration of
chromatin structure. Methylation of genomic DNA, his-
tone acetylation, and histone methylation are assumed to
have a large impact on the accessibility of DNA for tran-
scription initiation [9]. Such epigenetic mechanisms can
affect large genomic regions by possibly either silencing or
activating large arrays of genes. However, the regulatory
mechanisms governing chromatin assembly and disas-
sembly are only beginning to emerge. So far, due to meth-
odological limitations it has not been possible to study
the role of such phenomena for gene expression in cancer
cells on a genome-wide scale. Nevertheless, evidence from
single-gene focused studies suggests that chromatin regu-
lation does play an important role in tumorigenesis
[10,11].
Regardless of which mechanism leads to coordinated
expression in chromosomal domains, solely the knowl-
edge about such domains is of considerable importance.
Such knowledge could guide further studies that aim to
differentiate between those differentially expressed genes
that cause tumorigenesis and are the primary targets of
regional genomic aberrations and those that are rather the
outcome than the cause of tumor development. The
rationale for the existence of such piggy-back genes is the
following. The silencing of genes at close distance to a
known tumor suppressor gene (TSGs) would in many
cases just be a side effect of TSG silencing. A similar rea-
soning applies to oncogenes that can be activated by
increased expression: genes that are co-amplified could
also be expressed at higher levels although they do not
contribute to tumorigenesis. Typical searches for differen-
tially expressed genes by microarrays usually ignore such
piggy-back effects. This may lead to the identification of
large numbers of differentially expressed genes (DEGs), of
which only a smaller fraction is causative for tumor devel-
opment.
Though some experimental data recently became availa-
ble linking microarray expression with DNA copy number
analyses in some solid tumors [12-16] the knowledge
about the existence of genomic islands of coordinated
expression in colorectal carcinoma (CRC) is still limited.
During the preparation of this manuscript a first assess-
ment of chromosomal expression patterns in CRC in con-
junction with genome-wide DNA copy number analyses
became available [17]. Tsafrir et al. described a correlation
of gene copy number and expression for both, deleted and
amplified genes. They claimed that the described altera-
tions become more frequent as the tumors progress from
benign to metastatic forms, highlighting the need for a
more precise characterization of regions of coordinate
expression and gene copy number change. In addition to
this most recent work, a substantial body of literature on
chromosomal aberrations in CRC has accumulated
[7,15,18-25] that could help to interpret findings on
islands of coordinated chromosomal expression.
The need for a more precise definition of chromosomal
regions of altered gene expression prompted us to find a
new approach to investigate chromosomal co-expression
domains in CRC. The focus of our study was the identifi-
cation of up- or down-regulated gene expression in pri-
mary colon carcinoma cells compared to normal colon
epithelia of the same patient. By using laser capture micro-
dissection (LCM) we aimed to investigate transcript abun-
dance in relatively pure cell populations, trying to
minimize the influence of contaminating stroma tissue or
infiltrating peripheral blood cells on expression measure-
ments. The use of Affymetrix DNA microarray technology
allowed us to simultaneously assess mRNA levels of all
known human genes using only small amounts of cells
obtained by LCM. Finally, we developed a new bioinfor-
matic approach to identify regions of chromosomal
deregulation which enabled the most precise survey of
chromosomal expression domains in colon cancer availa-
ble today. In particular, we were interested in the question
whether our data correlated with the data of Tsafrir et al.
who performed genome scale arrayCGH and chip-based
expression analyses on a different set of colorectal cancer
patients [17]. In contrast to Tsafrir et al. we put more
emphasis on the identification of precise boundaries of
expression domains and therefore we consider our work
as complementary to their pioneering study.
Results
Evaluation of data set quality by tissue-wise hierarchical 
clustering
Prior to the analysis of chromosomal expression domains,
we aimed to check whether the quality of our complete
array expression data set (> 44 k genes) allows to extract
discrepancies between tumor samples and normal epithe-
lial tissues. Purely unsupervised hierarchical clustering ofMolecular Cancer 2006, 5:37 http://www.molecular-cancer.com/content/5/1/37
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tissue samples based on gene expression vectors can pro-
vide such information. The use of the full set of 44 k genes
for clustering is not desirable, because of high signal-noise
ratios and computational considerations. Therefore, we
pre-selected potentially informative genes for hierarchical
clustering. We selected only genes which had reliable
information about genomic localization and for which
probe sets exceeded a minimum expression threshold in
at least 20% of the experiments. To enrich informative
genes for tissue distinction, we required a minimum
standard deviation across all 50 samples. The pre-selec-
tion resulted in 514 probe sets. Note that we avoided to
pre-select genes based on differential expression between
tumor and normal tissue. We applied three rounds of nor-
malization to genes and arrays. Finally, we applied stand-
ard centroid hierarchical clustering (Pearson correlation)
to this dataset. Two large clusters were revealed (Figure 1).
18 out of 25 normal tissues formed one single cluster. The
remaining 8 normal tissues mainly clustered together with
matching tumor samples from same patients. This sug-
gests that coalescence between tumor and normal samples
from the same patients could be due to patient-specific
gene expression characteristics. As the majority of normal
samples could be clearly separated from tumors, we con-
cluded that our data set is well suited to explore differ-
ences in gene expression between normal and tumor cells
of colorectal origin.
Global search for chromosomal islands with up- or down-
regulation
Chromosome-scale analysis of gene expression (see Fig-
ures 2, 3, 4, 5) already suggested that there are many
regions of misregulated expression in our CRC samples.
The detailed analysis of expression along the chromo-
some in windows of sizes 5, 11, 21, 31, 41, 51 genes
resulted in the identification of 251 partially overlapping
intervals of up- or down-regulation (see Additional file 1).
These intervals were condensed in 81 non-overlapping
regions of expression imbalance: 43 regions with loss of
expression and 38 regions with gain of expression (see
Table 1). We determined the fraction of affected genes on
each chromosome (see Table 2). In total, 25.3% of all
genes under consideration show expression imbalance.
Slightly more genes lie in chromosomal regions that show
loss of expression (13.3%) than gain (12%) of expression.
The fractions of genes with gain or loss of expression vary
strikingly from chromosome to chromosome. Chromo-
somes 9, 10, 15, 18, and 22 showed only regional expres-
sion loss, whereas 8, 13, 20, and X showed only regional
increase in expression. There were too few informative
genes on chromosome Y to carry out a full analysis using
all window sizes, but small window sizes did not reveal
significant deregulation.
Individual chromosomal islands with gain of expression
8q11.23-q21.13
Gain of expression in region 8q11.23-q21.13 is strongest
in a small interval (8q12.1) that spans genes from TCEA1
to PLAG1 (see Figures 6, 7, 8). There have been numerous
reports of copy number gains of chromosome 8q in CRC
[18,21,23,25] which suggests a possible mechanism lead-
ing to over-expression in our patients. The known blood
cell oncogene LYN is located in this interval and it is up-
regulated in several of our tumor samples. It has been
reported before that LYN is expressed in colorectal tumors
[26]. The concerted up-regulation of LYN along with other
genes in this region suggests a role for LYN in CRC.
Another interesting gene in this interval is PLAG1 (pleo-
morphic adenoma gene 1) for which chromosomal aber-
rations have been described that lead to over-expression
in salivary gland tumors [27,28]. No informative expres-
sion measures were obtained for the MOS protein kinase
gene which is located between RPS20 and PLAG1,
although this may be due to technical limitations. Genes
encoding components of the translation machinery, the
mitochondrial ribosomal protein MRPL15 and cytosolic
ribosomal proteins RPL7 and RPS20, are located in this
region, highlighting the need for enhanced translation in
cancer cells. The concomitant down-regulation of the TOX
and ANKTM1 genes in many patients in an environment
of transcriptional activation is remarkable, but the func-
tional significance remains unclear. Buffart et al. have
reported amplifications of 8q11-q24 in metastasizing
CRC [29], highlighting a possible mechanism for gain of
expression in this region. In summary, our analysis sug-
gests that chromosomal region 8q12.1 is a candidate tar-
get region for genetic alterations that lead to over-
expression in CRC.
20q11.22-q11.23
The region 20q11.22-q11.23 was among the most fre-
quently up-regulated regions (see Figures 12, 13, 14).
Amplifications of regions on chromosome 20q have been
identified independently by several groups in CRCs
[19,21,23,24]. The interval comprises the known tumor
gene SRC (located between MANBAL and BLCAP in Fig-
ures 12, 13, 14) for which no informative expression
measures were obtained. We note that it is possible that
the SRC gene is the primary target of up-regulation in our
CRC patients, the up-regulation of other genes being just
piggy-back effects. However, also the up-regulation of the
CTNN1L1 transcript could be of potential functional sig-
nificance for CRC development. CTNN1L1 shows partial
homology to the known colorectal cancer gene beta-cat-
enin in the armadillo repeat region and has a nuclear
localization signal, suggesting that it could play an impor-
tant role in signal transduction to the nucleus in CRC.
Also up-regulation of the E3 ubiquitin ligase Itchy (ITCH)
could be of potential importance as selective ubiquitin-Molecular Cancer 2006, 5:37 http://www.molecular-cancer.com/content/5/1/37
Page 4 of 44
(page number not for citation purposes)
Hierarchical clustering of samples from colorectal tumors and normal colon epithelia Figure 1
Hierarchical clustering of samples from colorectal tumors and normal colon epithelia. On the right, you find the 
chromosomal localization of the genes and the official HUGO symbol or prospective Affymetrix cluster ID. On the top, the 
binary tree of tissue samples based on gene expression is given. The tissue denominators either contain TR for tumor or E for 
epithelium and a code reflecting the identity of each patient. In the center, the expression values after normalization have been 
color-coded: light blue means high expression, black means low (or no) expression. Note that only a representative fraction of 
the 514 genes is visualized here (white bars replace some portions of original heat map). The right cluster contains only sam-
ples from normal colon epithelia, the left cluster is composed primarily of tumors along with some interspersed normal epithe-
lial samples. Note that misplaced normal tissue (E) samples often cluster along with matching tumor (TR) samples from the 
same patient.Molecular Cancer 2006, 5:37 http://www.molecular-cancer.com/content/5/1/37
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tagging of signaling proteins for destruction is an emerg-
ing mechanism in cancer biology. The need for acceler-
ated protein synthesis in cancer cells is reflected by the up-
regulation of the translation initiation factor EIF2S2.
Remarkably, we found dramatic down-regulation against
the regional trend of C20orf110 alias p53-inducible pro-
tein 2 (TP53INP2) whose expression is usually positively
controlled by the p53 protein. For unknown reasons p53
seems to be unable to induce TP53INP2 expression in the
majority of CRCs studied here.
12q14.2-12q22
We observed increased expression of genes in chromo-
somal region 12q14.2-12q22 (see Figures 15, 16, 17). The
MDM2 gene at 12q15 is a possible target of this misregu-
lation. However, within this large region there is a smaller
region at 12q21.1-q21.2 spanning eight genes that exhibit
exceptionally high expression in our tumor samples.
Among these is LGR5 alias GPR49, a G-protein coupled
receptor that has large leucine-rich repeats in its N-termi-
nus. We could confirm the up-regulation of GPR49 in
CRC by quantitative PCR and in-situ hybridization (data
not shown). This finding and the exceptional suitability of
G-protein-coupled receptors as drug targets make the
LGR5/GPR49 protein a potential target for future thera-
peutical approaches. We do not know of any other reports
that link this region to CRC.
17q21.33-17q23.2
The chromosomal interval 17q21.33-17q23.2 harbors
numerous up-regulated genes (see Figures 18, 19, 20).
Chromosomal gains of this region in CRC have been
described by two independent studies [21,25]. Up to 18 of
25 patients show up-regulation of expression in this
region. The known tumor gene NME1 (non-metastatic 1;
encoding the NM23A protein, a nucleoside diphosphate
kinase) is among the most frequently up-regulated genes
in this region. Also the paralogous genomic neighbor
NME2 which acts in the same pathway is strongly up-reg-
ulated. These two genes are possibly the primary targets of
regional expression up-regulation. However, up-regula-
tion of several other genes is also remarkable. The up-reg-
ulation of the mitochondrial ribosomal component
MRPS23 is notable as it is in agreement with other obser-
vations of up-regulation of genes acting in translation (see
above). Additionally, the RING finger gene FLJ20315/
RNF124, possibly encoding a novel E3 ubiquitin ligase,
and the suppressor of Ty 4 homologue 1 (SUPT4H1), a
putative human chromatin regulator that alters transcrip-
tion, are genes that are strongly up-regulated and could
have the potential to contribute to development of CRC.
Individual chromosomal islands with loss of expression
1p36.13-1p36.11
The most strongly down-regulated region in our study is
1p36.13-1p36.11 (see Figures 9, 10, 11). A larger chromo-
some region comprising this fragment has recently been
reported to be frequently deleted in CRC (see Tables 1 and
4). No tumor suppressor gene has been found yet. Our
data suggest multiple genes that could act as class II TSGs.
Several have been associated with proliferative processes
or even cancer before. The PLA2G2A encodes phospholi-
pase A2 group IIA which has been proposed as a TSG and
a marker for metastasis and patient survival in gastric can-
cer [30]. The E2F2 transcription factor is a known regula-
tor of TSGs and interacts specifically with the RB protein.
It plays an important role in the cell cycle. The CDC42
protein is a small Rho-like GTPase. It acts in intracellular
signaling and is involved in various processes like control
of morphology, migration, endocytosis, and the cell cycle.
Therefore, PLAG2A, E2F2 and CDC42 are the primary
candidate tumor suppressors in this region.
4p15.31-4p15.2
The region 4p15.31-4p15.2 is part of a larger region (see
Table 1) that showed marked down-regulation of expres-
sion in our tumor samples (see Figures 21, 22, 23). Full or
partial losses of chromosome 4 are well known phenom-
ena in the development of CRC [18,19,23,24]. One of the
strongly down-regulated genes in this region is the SLIT2
gene at 4p15.31 that encodes a membrane protein regu-
lating cellular migration. It has recently been described as
a new tumor suppressor gene in CRC, gliomas, lung and
breast tumors and seems to be transcriptionally inacti-
vated by epigenetic silencing [31-33]. In addition, several
other genes of this region could serve as candidate class II
tumor suppressor genes. The GPR125 gene encodes an
orphan G-protein coupled receptor that has a large extra-
cellular N-terminus with an immunoglobulin domain
and leucine-rich repeats, similar to GPR49 described
above. The PCDH7 gene belongs to the protocadherin
gene family. It encodes a transmembrane protein that has
seven extracellular cadherin repeats, suggesting that it is
involved in cellular adhesion and adhesion-dependent
intracellular signaling. The functions of genes in this
region suggest that this regional expression loss influences
adhesion and migration properties of cancer cells. Both,
epigenetic silencing and chromosomal aberrations are
potential mechanisms leading to expression loss in this
region.
18q21.2-18q23
There are several reports of loss of chromosome 18q in
CRC (see Tables 1 and 4). We found a smaller region of
expression down-regulation at 18q21.2-18q23 (see Fig-
ures 24, 25, 26). There is a hot spot for down-regulation
in direct vicinity of the BCL2 gene. Its special role in can-Molecular Cancer 2006, 5:37 http://www.molecular-cancer.com/content/5/1/37
Page 6 of 44
(page number not for citation purposes)
Whole-chromosome plots of running average of fractions of samples showing up-/down-regulation in tumor versus normal  samples (Chromosomes 1, 2, 3, 4) Figure 2
Whole-chromosome plots of running average of fractions of samples showing up-/down-regulation in tumor 
versus normal samples (Chromosomes 1, 2, 3, 4). For each chromosome you see a separate figure. Gray dots denote 
the number of patients with up- or down-regulation for a single gene. Orange/green lines represent a running average of these 
values. The plots are made to be easily comparable with whole-genome CGH plots (like e.g. those in Knösel et al. [21]) Further 
details of plot construction are described in the methods section.Molecular Cancer 2006, 5:37 http://www.molecular-cancer.com/content/5/1/37
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Whole-chromosome plots of running average of fractions of samples showing up-/down-regulation in tumor versus normal  samples (Chromosomes 5, 6, 7, 8, 9, 10) Figure 3
Whole-chromosome plots of running average of fractions of samples showing up-/down-regulation in tumor 
versus normal samples (Chromosomes 5, 6, 7, 8, 9, 10). For each chromosome you see a separate figure. Gray dots 
denote the number of patients with up- or down-regulation for a single gene. Orange/green lines represent a running average 
of these values. The plots are made to be easily comparable with whole-genome CGH plots (like e.g. those in Knösel et al. 
[21]) Further details of plot construction are described in the methods section.Molecular Cancer 2006, 5:37 http://www.molecular-cancer.com/content/5/1/37
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Whole-chromosome plots of running average of fractions of samples showing up-/down-regulation in tumor versus normal  samples (Chromosomes 11, 12, 13, 14, 15, 16) Figure 4
Whole-chromosome plots of running average of fractions of samples showing up-/down-regulation in tumor 
versus normal samples (Chromosomes 11, 12, 13, 14, 15, 16). For each chromosome you see a separate figure. Gray 
dots denote the number of patients with up- or down-regulation for a single gene. Orange/green lines represent a running 
average of these values. The plots are made to be easily comparable with whole-genome CGH plots (like e.g. those in Knösel 
et al. [21]) Further details of plot construction are described in the methods section.Molecular Cancer 2006, 5:37 http://www.molecular-cancer.com/content/5/1/37
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Whole-chromosome plots of running average of fractions of samples showing up-/down-regulation in tumor versus normal  samples (Chromosome 17,18,19,20,21,22,X,Y) Figure 5
Whole-chromosome plots of running average of fractions of samples showing up-/down-regulation in tumor 
versus normal samples (Chromosome 17,18,19,20,21,22,X,Y). For each chromosome you see a separate figure. Gray 
dots denote the number of patients with up- or down-regulation for a single gene. Orange/green lines represent a running 
average of these values. The plots are made to be easily comparable with whole-genome CGH plots (like e.g. those in Knösel 
et al. [21]) Further details of plot construction are described in the methods section.M
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) Table 1: Individual chromosomal islands of up- or down-regulation.
expression change start region end region start gene end gene potential tumor genes, hereditary CRC, known chromosomal imbalances
loss 1p36.33 1p36.32 TNFRSF18 ARHGEF16 amplification of 1p36.33-p32 in CRC [25] // deletion of 13p36.3 in 25% of neuroblastomas and 87% of cell lines [45] /
/ loss of expression and genomic deletion on 1p [17]
loss 1p36.13 1p36.11 PADI1 DKFZP434L0117 E2F2 // ID3 // loss of 1p36.1 in CRC [22, 25] // loss of expression and genomic deletion on 1p [17]
loss 1p35.1 1p34.3 HDAC1 PSMB2 LCK at 1p35.1 // hereditary CRC at 1p35 (OMIM 114500) // loss of expression and genomic deletion on 1p [17]
gain 1q32.1 1q41 PIGR DKFZp547M236 1q32 amplification involving MDM4 and CNTN2 in malignant gliomas [46]
gain 2p25.3 2p24.2 Hs.8379.0 VSNL1 hereditary CRC at 2p25 (OMIM 114500)
loss 2p11.2 2q12.1 MAT2A MGC11332 83% loss of 2p11 in mantle cell lymphoma [47] // loss in mantle cell lymphoma [48]
gain 2q31.3 2q32.2 SSFA2 NAB1 hereditary HNPCC3 at 22q31-q33 (OMIM 600258) // familial breast cancer at 2q (OMIM 114480)
gain 2q33.2 2q35 Hs.163603 AAMP familial breast cancer at 2q (OMIM 114480)
loss 2q37.3 2q37.3 SCLY FARP2 familial breast cancer at 2q (OMIM 114480)
gain 3p25.3 3p25.1 KIAA0121 CAPN7 amplification of 3p25.2 in CRC [25] // RAF1 at 3p25.2 // FBLN1 at 3p25.2
gain 3p25.1 3p24.2 RAFTLIN THRB
gain 3p24.2 3p23 FLJ20604 CLASP2
loss 3p21.31 3p21.31 CELSR3 NPR2L hereditary HNPCC2 at 3p21.3 (OMIM 609310) // RASFF1
gain 3p11.1 3q13.11 MGC26717 ALCAM frequent 3q11.2-q13.1 amplifications in cervix carcinomas [49]
loss 3q13.13 3q21.2 Hs.23762.0 ITGB5
loss 4p15.32 4p14 LAP3 Hs.118993 deletions of 4p14 in CRC [24] // SLIT2 at 4p15 is inactivated by hypermethylation in gliomas [33] // SLIT2 suppresses 
tumor growth [32] // loss of expression and genomic deletion on 1p [17]
loss 4q13.2 4q13.3 YT521 CXCL6 global loss of expression and genomic deletion on 4 [17]
loss 4q21.21 4q22.3 PRKG2 LIM transition of follicular B cell lymphoma to diffuse large cell lymphoma accompanied by 4q21-q23 deletions // global 
loss of expression and genomic deletion on 4 [17]
loss 4q34.1 4q35.2 HPGD Hs.130535 deletion of 4q34-q35 in colorectal cancer cell lines [25] // CASP3 at 4q34.3 // global loss of expression and genomic 
deletion on 4 [17]
loss 5q15 5q23.2 Hs.444378 Hs.97104 hereditary colorectal adenoma and carcinoma 1 (CRAC1) (OMIM 601228) at 15q15.3-q221 // APC at 5q21 // loss of 
expression and genomic deletion on 5q [17]
gain 5q31.1 5q31.3 HTGN29 Hs.443121 loss of expression and genomic deletion on 5q [17]
loss 5q31.3 5q33.1 NDFIP1 FLJ10290 amplification of 5q32-q34 in prostate cancer [50] // PDGFRB at 5q32 // loss of expression and genomic deletion on 5q 
[17]
gain 5q33.2 5q35.1 MRPL22 FBXW1B amplification of 5q32-q34 in prostate cancer [50] // loss of expression and genomic deletion on 5q [17]
gain 6p25.3 6p24.2 DUSP22 NEDD9 amplification of 6p25 in 24% of mantle cell lymphomas [47] // amplification of 6p25 in 75% of prostate 
cancers [51]
loss 6p22.3 6p22.2 CAP2 SLC17A4 most frequent amplification of 6p22.3 in bladder cancer arrayCGH study [52]
loss 6p21.32 6p21.32 PBX2 RAB2L
gain 6p21.31 6p21.2 HMGA1 RNF8 CDKN1A at 6p21.2 // PIM1 at 6p21.2
gain 6q23.3 6q24.2 DUFD1 Hs.12565 amplification of 6q23-q24 assosicated with short survival [22]M
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) gain 7p22.3 7p21.3 FLJ23471 ICA1 hereditary HNPCC4 at 7p22 (gene PMS2) // gain of expression and genomic amplification of 7 [17]
gain 7p21.2 7p15.3 ETV1 OSBPL3 amplification of 7p21 in mantle cell lymphomas [47] // amplification of 7p21 in osteosarcoma [53] // 
gain of expression and genomic amplification of 7 [17]
gain 7p14.3 7p13 LSM5 NPC1L1 gain of expression and genomic amplification of 7 [17]
loss 7q11.23 7q21.3 SRCRB4D CAS1 amplification of 7q11.1-q12 in metastatic CRC [24] // gain of expression and genomic amplification of 7 [17]
gain 7q31.31 7q33 FAM3C MGC5242 prostate cancer aggressiveness linked to 7q32-q33 [54] // gain of expression and genomic amplification 
of 7 [17]
gain 8q11.23 8q21.11 ATP6V1H ANKTM1 amplifications of 8q11-q24 in metastasing CRC [29] // LYN at 8q12.1 // MOS at 8q12.1 // familial breast 
cancer at 8q11 (OMIM 114480) // amplifications at 8q in CRC [18, 21, 23, 25] // gain of expression and 
genomic amplification of 8q [17]
gain 8q22.3 8q24.22 TIEG SLA amplifications of 8q11-q24 in metastasing CRC [29] // MYC at 8q24.21 // PVT1 at 8q24.21 // 
amplification of 8q23-q24 in prostate cancer [55]// gain of expression and genomic amplification of 8q 
[17]
loss 9p21.3 9p21.1 IFNA4 SMU-1 loss of 9p21 in CRC [25] // TUBE1 at 9p21 // CDKN2A alias p16INK4A at ??? // frequent deletion of 9p21 in prostate 
cancer [56] // deletion of 9p21.3 in bladder cancer [57]
loss 9p13.3 9p13.3 BAG1 OPRS1 frequent LOH at 9p13-p21 in melanoma [58]
loss 9q21.11 9q21.32 Hs.173519.0 Hs.522256 loss of 9q21-q22 in mantle cell lymphoma [59]
loss 9q34.11 9q34.11 FLJ14596 GPR107 ABL1 protooncogene at 9q34.12
loss 10p15.3 10p12.2 Hs.255096 Hs.57079.0 frequent LOH of 10p15 in gastric cancer [60] // telomerase repressor at 10q15.1 [61] // deletion of 10p14 in mantle 
cell lymphoma [47, 59] // OPTN at 10p14 [62]
loss 10q11.21 10q11.23 Hs.173866.0 MOB RET at 10q11.21 // LOH in prostate cancer at 10q11.21 [51]
loss 11p15.5 11p15.5 RNH MUC5AC hereditary CRC at 11p15.5 / HRAS at 11p15.5 // 11p15.5 methylation-dependent expression silencing and imprinting 
in phaeochromocytomas [63]
gain 11p15.5 11p15.4 CTSD SSA1 CTSD (Cathepsin D) at 11p15.5 // familial breast cancer at 11p15.5 (OMIM 114480)
gain 11p13 11p12 Hs.120054.
0
TRAF6 WT1 at 11p13
gain 11p11.2 11q12.1 ch-TOG CTNND1
loss 11q13.2 11q13.4 LOC338692 SKD3 BCL1 at 11q13.3 (anti-apoptotic, amplified in breast cancer) // CCND1 at 11q13.3 (amplified in breast cancer [64]) // 
FGF3 at 11q13
gain 11q14.1 11q21 Hs.26339.0 MTMR2
loss 11q23.3 11q23.3 AMICA HYOU1 frequent loss of 11q23.3-q25 in neuroblastoma [65] // loss of 11q23 in 33% of 73 tumor types [66]
loss 12p13.31 12p13.2 TPI1 CLEC1 CDKN1B (alias p27Kip1) at 12p13.2
loss 12p12.3 12q12 CGI-26 MADP-1 familial breast cancer at 12p12.1 (OMIM 114480)
gain 12q14.2 12q22 Hs.132260.
0
Hs.403150 MDM2 at 12q15 // validated up-regulation of GPR49 at 12q21.1
gain 12q22 12q23.3 USP44 KIAA1033
loss 12q23.3 12q24.11 SART3 Hs.18370.0 loss of 12q24 in pancreas tumors [55]
gain 13q14.11 13q22.1 LOC28350
8
PIBF1 RB1 at 13q14.2 // ARLT1 at 13q14 // gain of expression and genomic amplification of 13q [17]
gain 14q22.1 14q22.2 PSMC6 AND-1 14q22-q23 losses in 25% of tumor types [66]
Table 1: Individual chromosomal islands of up- or down-regulation. (Continued)M
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)
loss 14q24.1 14q24.3 Hs.369329 Hs.169812 hereditary CRC at 14q24.3 (OMIM 114500) // loss of 14q24-31 in CRC metastases [36] // FOS at 14q24.3 // 
hereditary HNPCC7 at 14q24.3 (gene MLH3) (OMIM) // poor prognosis when 14q24-q31 is lost in renal cell 
carcinoma [67] // loss of expression and genomic DNA of 14q [17]
loss 14q32.33 14q32.33 ZFYVE21 Hs.248015.0 14q32 is a tumor suppressive region in esophagal cancer [68] // loss of expression and genomic DNA of 14q [17]
loss 15q21.1 15q22.31 FBN1 CLPX association between loss of 15q21.1-q22.2 and survival in hepatocellular carcinoma [69] // allelic imbalance at 15q21.1 
in breast cancer metastases [70] // loss of expression and genomic DNA of 15q [17]
loss 15q26.1 15q26.3 GABARAPL
3
FLJ25222 loss of expression and genomic DNA of 15q [17]
loss 16p12.1 16p11.2 GTF3C1 PRSS8
loss 16q12.1 16q13 TRF4-2 FLJ13154
gain 16q22.1 16q22.2 PSMB10 KIAA0931 CDH1 (E-Cadherin) at 16q22.1
loss 17p13.3 17p13.2 RPA1 DHX33 loss of 17p13.2 in CRC [25] // DHX33 at 17p13.2
loss 17p13.1 17p11.2 GAS7 COPS3 Near TP53 at 17p13.1 .// hereditary CRC at 17p11.2 (OMIM 114500) // hereditary CRC at 17p13.1 (OMIM 114500) /
/ // familial breast cancer at 17p13 (OMIM 114480) // loss of 17p12 in CRC [25] // ELAC2 at 17p11.2
gain 17q21.33 17q23.2 TOB1 PPM1D NME1 (NME23) at 17q21.33 // familial breast cancer at 17q22-q23 (OMIM 114480) //
loss 18p11.21 18q12.1 MGC24180 DSC3 loss of expression and genomic DNA of 18 [17]
loss 18q21.1 18q23 CGBP MBP DCC at 18q21.3 (OMIM 120470) // loss of 18q21.1 in CRC cell lines [25] // SMAD2 // SMAD4 mutations in CRC [71] 
// loss of expression and genomic DNA of 18 [17]
loss 19p13.3 19p13.3 DF APCL
gain 19p13.2 19p13.12 FLJ20244 NOTCH3
gain 19p13.11 19q13.12 LOC11497
7
TYROBP NIFIE14 at 19q13.12
loss 19q13.2 19q13.32 MGC20255 TOMM40 AKT2 (breast carcinoma at 19q13.2 // TGFB1 at 19q13.2 // proapototic Bax at 19q13.33
gain 20p11.21 20q11.21 C1QR1 BCL2L1
gain 20q11.22 20q11.23 RNPC2 C20orf102 SRC at 20q11.23 (overexpressed in breast carcinoma) // gain of expression and genomic DNA of 20q 
[17]
gain 20q13.12 20q13.33 SLC12A5 ARFRP1 gain of expression and genomic DNA of 20q [17]
gain 21q22.12 21q22.3 C21orf18 TMPRSS2 ETS2 at 21q22.2
loss 21q22.3 21q22.3 PFKL COL6A1 COL18A1 (Endostatin) at 21q22.3
loss 22q11.21 22q12.1 SDF2L1 TPST2 familial breast cancer at 22q12.1 (OMIM 114480)
loss 22q13.31 22q13.33 Hs.296370.0 RABL2B hereditary CRC at 22q13 (OMIM 114500)
gain Xp22.13 Xp22.11 SCML1 ARX
gain Xp11.22 Xp11.1 Hs.3383.1 Hs.224455
gain Xq24 Xq26.3 FLJ32122 CXX1
These are condensed results of the ChARM analyses: overlapping regions with evidence for up- or down-regulation from various analyses of different cross-correlation window sizes have been fused into 
single regions. The original ChARM output including p values for each region and additional annotation can be found in Additional file 1. Hereditary colorectal cancer syndromes are indicated along with their 
OMIM ID. Gene symbols are official or provisional HUGO symbols if available, otherwise names of Unigene clusters. Information about known tumor genes in misregulated regions were extracted from the 
literature. Tumor-associated genes are located within expression islands or in near vicinity.
Table 1: Individual chromosomal islands of up- or down-regulation. (Continued)Molecular Cancer 2006, 5:37 http://www.molecular-cancer.com/content/5/1/37
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cer qualified the anti-apoptotic BCL2 protein as a thera-
peutic target molecule [34,35]. Here we observed down-
regulation of BCL2 and its neighbors which is contradic-
tory to its known anti-apoptotic cancer-promoting func-
tion. Distal to BCL2 at 18q21.1-18q21.2 there is a region
of less pronounced down-regulation between ME2 and
MBD2. The SMAD4 (Hs.298320) is only weakly down-
regulated and the biological significance is questionable.
The DCC (deleted in colorectal carcinoma), proximal to
MBD2, is the largest gene in this region, but no statements
about its expression can be made because of a lack of
informative expression measures. The SMAD2 and
SMAD7 genes are in close vicinity to this region. In sum-
mary, we do not have direct evidence for down-regulation
of tumor suppressor genes in this region. Instead, we
observed down-regulation of the cancer-promoting BCL2
gene. Therefore, the biological significance of this domain
of expression loss remains elusive. Possibly, the down-reg-
ulation of the BCL2 region is just a by-stander effect of
deletions targeted at DCC disruption. Alternatively, BCL2
down-regulation could be an unsuccessful attempt of the
tumor cells' genetic program to shift the cellular homeos-
tasis towards cell death.
5q22.2-5q23.1
Not unexpected, we found loss of expression in region
5q22.2-5q23.1 (see Figures 27, 28, 29). This interval har-
bors two known TSGs in colon cancer, the adenomatous
polyposis coli gene (APC) gene and the mutated in color-
ectal cancer (MCC). We were not able to obtain expres-
sion values for APC. APC is located at the border of a
region at 5q22.2-5q22.3 that harbors several drastically
down-regulated genes. Central in this region is the MCC
gene. The distal border is the CDO1 gene. We assume that
deletion or epigenetic silencing of this region is a frequent
mechanism contributing to colorectal tumorigenesis. It is
possible that also APC or MCC show reduced expression,
that genes in this region other than APC and MCC are
piggy-back genes, and that their misregulation is not of
functional significance for tumorigenesis.
14q24.3
The chromosomal region 14q24.3 has been implicated in
colorectal cancer several times (see Table 1). We found
coordinated down-regulation of expression of genes in
14q24.1-14q24.3 (see Figures 30, 31, 32). The region
comprises the MLH3 gene that is linked to hereditary non-
polyposis colorectal cancer type 7 (HNPCC7). We note
Table 2: Statistics on expression imbalances across human chromosomes.
Chromosome Genes Considered Genes In Regions With 
Expression Imbalance
Genes In Regions With 
Expression Gain
Genes In Regions With 
Expression Loss
chr1 2976 418 (14.0%) 109 (3.7%) 309 (10.4%)
chr2 2236 550 (24.6%) 296 (13.2%) 254 (11.4%)
chr3 1815 444 (24.5%) 203 (11.2%) 241 (13.3%)
chr4 1273 347 (27.3%) 0 (0.0%) 347 (27.3%)
chr5 1496 489 (32.7%) 219 (14.6%) 270 (18.0%)
chr6 1767 355 (20.1%) 240 (13.6%) 115 (6.5%)
chr7 1537 585 (38.1%) 451 (29.3%) 134 (8.7%)
chr8 1152 311 (27.0%) 311 (27.0%) 0 (0.0%)
chr9 1215 193 (15.9%) 0 (0.0%) 193 (15.9%)
chr10 1255 271 (21.6%) 0 (0.0%) 271 (21.6%)
chr11 1781 515 (28.9%) 328 (18.4%) 187 (10.5%)
chr12 1584 546 (34.5%) 279 (17.6%) 267 (16.9%)
chr13 683 180 (26.4%) 180 (26.4%) 0 (0.0%)
chr14 1061 206 (19.4%) 27 (2.5%) 179 (16.9%)
chr15 951 306 (32.2%) 0 (0.0%) 306 (32.2%)
chr16 1279 349 (27.3%) 103 (8.1%) 246 (19.2%)
chr17 1807 329 (18.2%) 120 (6.6%) 209 (11.6%)
chr18 546 246 (45.1%) 0 (0.0%) 246 (45.1%)
chr19 1636 339 (20.7%) 194 (11.9%) 145 (8.9%)
chr20 917 386 (42.1%) 386 (42.1%) 0 (0.0%)
chr21 358 118 (33.0%) 68 (19.0%) 50 (14.0%)
chr22 736 192 (26.1%) 0 (0.0%) 192 (26.1%)
chrX 1042 217 (20.8%) 217 (20.8%) 0 (0.0%)
chrY 96 0 (0.0%) 0 (0.0%) 0 (0.0%)
TOTAL 31199 7892 (25.3%) 3731 (12.0%) 4161 (13.3%)
Here, estimates of portions of chromosomes that are affected by regional regulation of expression are given. The second column gives the number 
of genes on a particular chromosome that were included in our analysis. The following columns contain the numbers of genes that are located in 
deregulated expression islands (up/down).Molecular Cancer 2006, 5:37 http://www.molecular-cancer.com/content/5/1/37
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that also the FOS gene encoding one half of the bZIP
dimer activator protein (AP-1) at 14q24.3 is strongly
down-regulated. FOS is known as an oncogene and its
down-regulation is therefore unexpected. However, dele-
tions of 14q24.3 have been linked to metastatic CRC [36].
In combination, these results suggest that there is a class II
tumor metastasis suppressor in this region. This class II
TSG is probably not MLH3, as its protein function is
hardly related to cellular functions promoting metastasis.
The functions of several other strongly misregulated pro-
teins, however, make them better candidates for metasta-
sis suppressors. KIAA0317 codes for a predicted
transmembrane ubiquitin ligase. Ubiquitin ligases can
help to tag misfolded transmembrane proteins in the ER
for destruction via the proteasome system [37]. Absence
of such a function could result in misexpressed proteins at
the cell surface which could promote metastasis. Other
potential candidates for metastasis suppressor genes in
this region code for the transmembrane Alzheimer pro-
tein PSEN1, the GTPase activating protein KIAA0440/
SIPA1L1, the PDZ-domain synaptojanin 2-binding pro-
tein SYNJ2BP and the developmental regulator and Notch
interaction partner NUMB.
Discussion
Global analysis of chromosomal regions with expression 
gain or loss
We found that 25% of the genes lie in regions that are
affected by expression imbalance in colon cancer. This
does not mean that 25% of the genes are misregulated as
Up-regulation of mRNA expression in human chromosomal region 8q11.23-q21.13 (T/N relative expression heat map) Figure 6
Up-regulation of mRNA expression in human chromosomal region 8q11.23-q21.13 (T/N relative expression 
heat map). Heat map of fold change of tumor-versus-normal expression. Genes are given in chromosomal order on the hor-
izontal axis. Patient codes are given on the vertical axis. The legend depicts which colors code for which expression changes on 
a loge scale (green: down in tumor; red: up in tumor). View in conjunction with Figures 7 and 8.Molecular Cancer 2006, 5:37 http://www.molecular-cancer.com/content/5/1/37
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many genes that fall into these regions are not expressed
at all in tumors and in normal epithelium of the colon.
Additionally, we note that these numbers are probably an
upper limit because the sliding window approach proba-
bly included several genes in close proximity to the
boundaries of misexpressed regions. Nevertheless, the
number of regions of imbalanced expression is remarka-
ble and suggest that there is extensive regulation in CRC at
Up-regulation of mRNA expression in human chromosomal region 8q11.23-q21.13 (patient counts with coordinate up-regula- tion) Figure 7
Up-regulation of mRNA expression in human chromosomal region 8q11.23-q21.13 (patient counts with coor-
dinate up-regulation). Grayscale plot of cross-comparison of up-regulation patterns across patients for gene pairs in a par-
ticular region. Both, horizontal and vertical axes comprise the same genes in chromosomal order. In each square total counts 
of patients with consistent up-regulation in two genes are coded by different shades of gray. Dark squared regions along the 
diagonal indicate coordinated regulation in patient subgroups. Note, that many more patients show up-regulation as indicated 
by dark spots in this figure than down-regulation as indicated by dark spots in Figure 8. The left region of exceptionally strong 
up-regulation spans TCEA1, LYPLA1, MRPL15, the known tumor gene LYN, and PLAG1. Note that TOX and ANKTM1 are 
down-regulated in approximately half of the tumor samples.Molecular Cancer 2006, 5:37 http://www.molecular-cancer.com/content/5/1/37
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the genomic level. Recently, Nakao et al. estimated from
genome-wide array CGH data that ~17% of the human
genome is affected by DNA copy number changes in CRC
[23]. Prior to a more detailed analysis of individual
regions in this study, this suggested that not all regional
expression changes in CRC will be explainable by DNA
copy number aberrations.
There are only slightly more genes with expression loss
than regions with expression gain. One can argue that a
tumor ought to show a higher frequency of expression
loss than expression gain. Reasons are that there should
be a tendency to lose tumor suppressor genes selectively
and to lose non-essential genes (genomic ballast) as a side
effect. If transcription would be a process that is predom-
Up-regulation of mRNA expression in human chromosomal region 8q11.23-q21.13 (patient counts with coordinate down-reg- ulation) Figure 8
Up-regulation of mRNA expression in human chromosomal region 8q11.23-q21.13 (patient counts with coor-
dinate down-regulation). Grayscale plot of cross-comparison of down-regulation patterns across patients for gene pairs in 
a particular region. Both, horizontal and vertical axes comprise the same genes in chromosomal order. In each square total 
counts of patients with consistent down-regulation in two genes are coded by different shades of gray. Dark squared regions 
along the diagonal indicate coordinated regulation in patient subgroups. View in conjunction with Figures 6 and 7.Molecular Cancer 2006, 5:37 http://www.molecular-cancer.com/content/5/1/37
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inantly driven by positive regulation of transcriptional
activators, one would assume that any partial genome loss
results in a slow down of transcription. In the light of
these considerations, an equally high number of regions
with expression gain can be interpreted in two ways.
Either positive selection drives expression gain of some
regions in cancer cells, or a default phenotype of transcrip-
tion suppression dominates in normal cells which is
relaxed during tumor cell development.
Gene expression in chromosomal regions with frequent 
DNA copy number changes in CRC
Most studies reported frequent gains of chromosome 7,
8q, 13q, 20q and losses of 4 and 18q in CRC [18,19,21-
25]. These broadly-defined alterations are in perfect agree-
ment with chromosome-specific trends in our expression
data, especially the exclusive presence of domains of
expression gain on 8, 13 and 20 and the exclusive pres-
ence of domains of expression loss on chromosome 4 and
18 (see Table 2 and Figures 21, 22, 23, 24, 25, 26). There
is a single discrepancy for chromosome 7: region 7q11-
7q12 has been reported as amplified in CRC, but its
expression is significantly down-regulated in our tumor
samples.
For a more detailed survey of congruence between gene
expression and chromosomal aberrations in CRC, we
compared our results to six previous studies reporting
chromosomal gains or losses in distinct chromosomal
regions [18,19,21-25] (see Tables 3, 4). We considered
only those chromosomal regions that were reported by
different researchers or were found to be aberrant in >
Up-regulation of mRNA expression in human chromosomal region 20q11.22-q11.23 (T/N relative expression heat map) Figure 12
Up-regulation of mRNA expression in human chromosomal region 20q11.22-q11.23 (T/N relative expression 
heat map). Heat map of fold change of tumor-versus-normal expression. Genes are given in chromosomal order on the hor-
izontal axis. Patient codes are given on the vertical axis. The legend depicts which colors code for which expression changes on 
a loge scale (green: down in tumor; red: up in tumor). View in conjunction with Figures 13 and 14.Molecular Cancer 2006, 5:37 http://www.molecular-cancer.com/content/5/1/37
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20% of tumor samples. In summary, we found that the
majority of deletion regions show a reduction in expres-
sion. This suggests that regional transcriptional silencing
in CRC is mainly achieved by loss of genomic DNA. In
contrast, amplified regions rather show heterogeneous
expression changes. We found regions of expression gain
in the most frequently reported regions of chromosome
gain on 7, 8q, 13, 20q. These regions are in support for a
Up-regulation of mRNA expression in human chromosomal region 20q11.22-q11.23 (patient counts with coordinate up-regu- lation) Figure 13
Up-regulation of mRNA expression in human chromosomal region 20q11.22-q11.23 (patient counts with coor-
dinate up-regulation). Grayscale plot of cross-comparison of up-regulation patterns across patients for gene pairs in a par-
ticular region. Both, horizontal and vertical axes comprise the same genes in chromosomal order. In each square total counts 
of patients with consistent up-regulation in two genes are coded by different shades of gray. Dark squared regions along the 
diagonal indicate coordinated regulation in patient subgroups. Note, that many more patients show up-regulation as indicated 
by dark spots in this plot than down-regulation as indicated by dark spots in Figure 14. The known most frequently up-regu-
lated genes in this region are EIF2S2, AHCY, ITCH, DNCL2A, ITG4BP, C20orf24, NDRGL3, RPN2 and CTNNBL1. Also note 
the gene C20orf110 alias TP53INP2 which is down-regulated in the majority of tumors.Molecular Cancer 2006, 5:37 http://www.molecular-cancer.com/content/5/1/37
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positive correlation of DNA copy number and transcript
abundance, although a direct causal relationship is not
shown in this study.
However, there are also many regions of frequent dele-
tions that did not show alterations in expression or that
were even down-regulated (7q11.2-7q12, 9q34, 12p13.1-
13.2, 15q22-15q23, 16p12-16p11, 22q11; compare
Tables 3 and 4). One possible explanation is that these
down-regulated regions are not amplified in our tumor
samples. An alternative explanation is that the influence
of chromosomal amplification on transcription levels can
be either positive or negative. It is possible that amplifica-
tion of a particular genomic region disrupts transcription
Up-regulation of mRNA expression in human chromosomal region 20q11.22-q11.23 (patient counts with coordinate down- regulation) Figure 14
Up-regulation of mRNA expression in human chromosomal region 20q11.22-q11.23 (patient counts with coor-
dinate down-regulation). Grayscale plot of cross-comparison of down-regulation patterns across patients for gene pairs in 
a particular region. Both, horizontal and vertical axes comprise the same genes in chromosomal order. In each square total 
counts of patients with consistent down-regulation in two genes are coded by different shades of gray. Dark squared regions 
along the diagonal indicate coordinated regulation in patient subgroups. View in conjunction with Figures 12 and 13.Molecular Cancer 2006, 5:37 http://www.molecular-cancer.com/content/5/1/37
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of amplified genes by a yet unknown mechanism, e.g. by
induction of chromatin-based silencing, or by separation
of essential enhancer regions from transcription starts.
Platzer et al. found amplifications in 7p, 8q, 13q, 20q in
26%–43% of their CRC patients and revealed by microar-
ray-based expression analysis that only 81 of 2146 genes
in amplified regions show over-expression (3.8%)
whereas 164 of 2146 genes show under-expression
(7.7%). Using a different approach (microdissection,
oligo arrays, analysis aimed at the identification of single
chromosomal expression domains and not at the location
of all differentially expressed genes in chromosomes) we
found several smaller up-regulated regions and no regions
of down-regulation in the same chromosomal regions.
Therefore, our data partly contradicts the findings of
Platzer et al. which state that in these frequently amplified
regions gene expression is rather down-regulated. How-
ever, other misregulated expression domains (see above)
of our study confirmed the general notion by Platzer et al.
that frequently amplified regions in CRC can also exhibit
down-regulation of transcript levels.
Aberrantly expressed chromosomal islands linked to 
hereditary cancer
Roughly 5% of all colorectal carcinomas are hereditary
non-polyposis colorectal cancers (HNPCCs). In HNPCC,
histologically verified colorectal carcinoma is found in at
least three relatives from two or more successive genera-
tions. In at least one patient, the age of onset should be
less than 50 years. Seven chromosomal regions have been
linked to HNPCC. More than half of these HNPCC
regions show misregulated expression in our patients.
Three regions show down-regulation (3p21.3, 2q31-q33
comprising PMS1, 14q24.3 comprising MLH3), one
region shows up-regulation (7p22 comprising PMS2),
and three regions do not show significant changes in
expression (2p22.p21 comprising MSH2, 2p16 compris-
ing MSH6, 3p22 comprising TGFBR2). Eleven further
chromosomal regions are linked to hereditary colorectal
carcinoma under a common entry in OMIM (14500).
More than 50% of these regions show significant expres-
sion changes in our data. Five regions show down-regula-
tion (1p35, 14q24.3, 17p11.2, 17p13.1, 22q13), one
region shows up-regulation (2p25), and five regions do
not show significant expression changes in our data
(3q26.3, 8p22-p21.3, 11p11.2, 15q15, 17q24). In combi-
nation, these findings strongly suggest that expression
changes in regions linked to hereditary CRC play a role in
CRC development.
Congruence of our study with the genome-wide copy 
number and expression analysis of Tsafrir et al
A particular focus of our study was on the congruence of
our data with that of Tsafrir et al. [17]. These authors
described 11 alterations of whole chromosomes or chro-
mosome arms. Using our approach based solely on
expression data we found precisely defined region of coor-
dinated up-regulation in all four regions of gene expres-
sion and gDNA copy number gain that they reported (+7,
+8q, +13q, +20q). For six of seven aberrations (-1p, -4, -
5q, -14q, -15q, -18) we discovered smaller expression
Up-regulation of mRNA expression in human chromosomal  region 12q21.1-q21.2 (T/N relative expression heat map) Figure 15
Up-regulation of mRNA expression in human chro-
mosomal region 12q21.1-q21.2 (T/N relative expres-
sion heat map). Heat map of fold change of tumor-versus-
normal expression. Genes are given in chromosomal order 
on the horizontal axis. Patient codes are given on the vertical 
axis. The legend depicts which colors code for which expres-
sion changes on a loge scale (green: down in tumor; red: up in 
tumor). View in conjunction with Figures 16 and 17.Molecular Cancer 2006, 5:37 http://www.molecular-cancer.com/content/5/1/37
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islands of coordinated down-regulation. We were not able
to reproduce the finding of expression loss on 8p. In sum-
mary, this large congruence of our results with that of Tsa-
frir et al. can be regarded as an external validation of our
results. The comparison illustrates the power of our data
analysis approach which allows to define expression
islands on a single-gene resolution. Most importantly it
confirms our confidence in the use of the chip platform
(Affymetrix U133A) that was used in both studies and
apparently can lead to largely congruent results in differ-
ent patient cohorts and laboratories.
Conclusion
Roughly a quarter of all human genes is located in islands
of misregulated gene expression in colorectal cancer.
There are only slightly more down-regulated than up-reg-
ulated genes. Chromosomal regions that are linked to
hereditary colorectal cancer often exhibit deregulated
Up-regulation of mRNA expression in human chromosomal region 12q21.1-q21.2 (patient counts with coordinate up-regula- tion) Figure 16
Up-regulation of mRNA expression in human chromosomal region 12q21.1-q21.2 (patient counts with coordi-
nate up-regulation). Grayscale cross-comparison plots of up-regulation patterns across patients (analogous to Figures 7, 10 
and 13). View this plot in conjunction with Figures 15 and 17. Note, that many more patients show up-regulation as indicated 
by dark spots in this plot than down-regulation as indicated by dark spots in Figure 17. Over-expressed genes in this region 
comprise leucine-rich G-protein coupled receptor 5 (GPR49), HIV-1 rev binding protein 2 (HRB2), pleckstrin-homology-like 
domain family A member 1 (PHLDA1), nucleosome assembly protein 1-like 1 (NAP1L1), oxysterol binding protein-like 8 
(OSBPL8), cystein- and glycine-rich protein 2 (CSRP2), E2F transcription factor 7 (LOC144455).Molecular Cancer 2006, 5:37 http://www.molecular-cancer.com/content/5/1/37
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expression, suggesting that they are implicated in sponta-
neous CRC not only through collection of mutations.
Thus, genes in these chromosomal hotspots may be sys-
tematically tested in patients with sporadic CRC for
molecular lesions and for transcriptional silencing.
Chromosomal regions that are frequently deleted in CRC
very often comprise islands in which we found reduced
expression. Although many regions that are known to be
amplified in colorectal tumors show a gain of expression,
there are also a considerable number of amplified islands
that show no alterations or even down-regulation. Com-
parison of published CGH studies with our expression
data suggests that amplified or deleted chromosomal
regions are responsible for many islands with aberrant
expression. However, we suggest that it is necessary to
invoke other mechanism like epigenetic regulation of
chromatin or disruption of enhancer actions to explain
the remaining expression imbalances.
Up-regulation of mRNA expression in human chromosomal region 12q21.1-q21.2 (patient counts with coordinate down-regu- lation) Figure 17
Up-regulation of mRNA expression in human chromosomal region 12q21.1-q21.2 (patient counts with coordi-
nate down-regulation). Grayscale cross-comparison plots of down-regulation patterns across patients (analogous to Figures 
8, 11, 14). View this plot in conjunction with Figures 15 and 16.Molecular Cancer 2006, 5:37 http://www.molecular-cancer.com/content/5/1/37
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Methods
Patients
25 colorectal cancer patients undergoing elective standard
oncological resection at the department of surgery, Char-
ité, Campus Benjamin Franklin, Berlin, Germany were
prospectively recruited for this study. The study was
approved by the local ethical committee and informed
consent was obtained from all patients. Rectal cancer
patients receiving neo-adjuvant radiochemotherapy were
excluded from this study.
Tissue samples and UV-laser microdissection
Transmural cancer specimens were snap frozen (liquid
nitrogen) within 20 minutes following excision and
stored at -80°C. All tissue samples were evaluated by a
pathologist before and during laser micro-dissection to
ensure an enrichment of vital tumor cells. Six-micron
serial frozen sections were cut on a standard cryostat and
mounted on RNase-free foil (2,5 μm) coated on glass
slides followed by immediate fixation (70% ethanol for
30s), H&E staining, and ethanol dehydration (70%, 95%
and finally 100% ethanol). After vacuum drying the mem-
branes carrying the sections were manually turned and
coated on new RNase free glass slides. Optically transpar-
ent CapSure LCM caps (ARCTURUS, CA) were placed on
the foil over a selected field of cells. Vital colorectal epithe-
lial carcinoma cells (> 90% proportion) from the invasion
front were isolated using UV-LCM Systems from PALM
Up-regulation of mRNA levels in human chromosomal region 17q21.33-23.2 (T/N relative expression heat map) Figure 18
Up-regulation of mRNA levels in human chromosomal region 17q21.33-23.2 (T/N relative expression heat 
map). Heat map of fold change of tumor-versus-normal expression. Genes are given in chromosomal order on the horizontal 
axis. Patient codes are given on the vertical axis. The legend depicts which colors code for which expression changes on a loge 
scale (green: down in tumor; red: up in tumor). View in conjunction with Figures 19 and 20.Molecular Cancer 2006, 5:37 http://www.molecular-cancer.com/content/5/1/37
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(Microlaser Technologie, Germany) and SL (Microtest
GmbH, Germany). After visual control of completeness of
dissection the captured cells were immersed in denatura-
tion buffer (GTC Extraction Buffer, 2% beta-mercaptoeth-
anol, Promega, WI) and stored at -80°C.
mRNA-extraction, cRNA-preparation and -amplification
Poly(A)+ RNAs were isolated using PolyATtract 1000 kit
(Promega, Heidelberg, Germany) according to the manu-
facturer's recommendations. For each sample the cDNA
synthesis and repetitive in vitro transcription were per-
formed three times, as described previously [38-40]. In
brief, the total amount of prepared mRNA from one sam-
Up-regulation of mRNA levels in human chromosomal region 17q21.33-23.2 (patient counts with coordinate up-regulation) Figure 19
Up-regulation of mRNA levels in human chromosomal region 17q21.33-23.2 (patient counts with coordinate 
up-regulation). Grayscale cross-comparison plots of up-regulation patterns across patients (analogous to Figures 7, 10, 13). 
View this plot in conjunction with Figures 18 and 20. Note, that many more patients show up-regulation as indicated by dark 
spots in this plot than down-regulation as indicated by dark spots in Figure 20. This region has been reported in other studies 
to be frequently amplified in colon cancer (see Table 3).Molecular Cancer 2006, 5:37 http://www.molecular-cancer.com/content/5/1/37
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ple was used. First strand cDNA synthesis was initiated
using the Affymetrix T7-oligo-dT promoter-primer combi-
nation. The second strand cDNA was synthesized by inter-
nal priming. In vitro transcription was performed using
Ambion's Megascript kit (Ambion, Huntington, UK) as
recommended by the manufacturer. From the generated
cRNA a new first strand synthesis was initiated using
0.025 mM of a random hexamer as primer. After comple-
tion, the second strand synthesis was primed using the
Affymetrix T7-oligo-dT promoter-primer combination at
a concentration of 0.1 mM. A second in vitro transcription
was performed and then the procedure was repeated one
additional time. During the third in vitro transcription
biotin-labeled nucleotides were incorporated into the
cRNA as recommended by the Affymetrix protocol.
Up-regulation of mRNA levels in human chromosomal region 17q21.33-23.2 (patient counts with coordinate down-regulation) Figure 20
Up-regulation of mRNA levels in human chromosomal region 17q21.33-23.2 (patient counts with coordinate 
down-regulation). Grayscale cross-comparison plots of down-regulation patterns across patients (analogous to Figures 8, 
11, 14). View this plot in conjunction with Figures 18 and 19.Molecular Cancer 2006, 5:37 http://www.molecular-cancer.com/content/5/1/37
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Microarray hybridization
BIO+cRNAs were hybridized on Affymetrix Human
Genome U133A and U133B GeneChips, that consist of
44.928 probe sets (Affymetrix, Santa Clara, CA). Fragmen-
tation, preparation of hybridization cocktails, hybridiza-
tion, washing, staining and scanning of Affymetrix
GeneChip were performed according to the manufac-
turer's protocols.
Preprocessing of expression data
We used our own algorithm to condensate the probe level
data provided by Affymetrix CEL-files per chip experi-
ment: Background intensity was computed as the mean of
the 2% darkest feature intensities. This background value
was subtracted from each feature value. Subsequently,
each feature value was divided by the median of all feature
values. As a representative expression value (PMQ) for
each probe set, the third quartile (75%) of all intensities
of all perfect match oligonucleotides was used. Further-
more, to distinguish real expression signals from noise the
Wilcoxon signed rank test was applied to each probe set.
A probe set was called detectable if the result of the Wil-
coxon signed rank test applied to its 11 probe pairs (per-
fect match versus mismatch oligonucleotide) had a
significance level of p < 0.1 and relative expression value
(PMQ) of > 4.0. We used these constraints for decision
whether a gene is expressed or not due to validation
results of several gene expression pattern by quantitative
Table 4: Expression in Islands frequently deleted in CRC.
chromosomal region fraction of patients with deletions congruent with our expression data CGH study
1p yes [17]
1p36.2-1p36.1 21% yes [22]
1p21-1p22 72% no [21, 24]
3p12 66% no [21, 24]
4 – yes [15, 17, 18]
4p 42% yes [19]
4p14 87% yes [21, 24]
4q 58% yes [19]
4q27-4q28 96% no [21, 24]
4q31.3 39% no [22]
4q34.3 38% yes [25]
4q35 34% yes [22]
5q > 35% yes [17, 23]
5q21 81% yes [21, 24]
6q16-6q21 72% no [21, 24]
8p 37% no [17, 18, 23, 25]
8p24-8p21 66% no [21, 24]
9p21 64% yes [21, 24]
9p22 25% no [22]
10q26.2 22% no [25]
11q13.1 30% no [25]
14q yes [17]
14q13-14q21 64% yes [21, 24]
15q yes [17]
17p 46% yes [23]
17p13.2 51% yes [25]
17p12 32% yes [25]
18 yes [17]
18p 49% yes [23]
18q 60% yes [23]
18q 32% yes [18, 25]
18q 92% yes [19]
18q11.2 72% no [22]
18q12.2 59% no [25]
18q21-18q23 96% yes [21]
18q21.1 60% yes [25]
21q > 35% yes [23]
21q21 74% no [21, 24]
Literature survey of chromosomal regions with evidence for deletions in colorectal cancers. We checked all regions of frequent chromosomal 
deletions for congruence with expression patterns. Congruence between literature CGH data and our expression data was declared on the 
presumption that allelic loss causes mRNA down-regulation.Molecular Cancer 2006, 5:37 http://www.molecular-cancer.com/content/5/1/37
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RT-PCR and/or Northern Blot analysis in our lab (data not
shown).
For each patient and probeset an expression ratio was cal-
culated according to the following rules: If expression was
detectable in both the normal and tumor sample (Wil-
coxon test p <= 0.10 and relative expression value PMQ >=
4), the ratio PMQ(T)/PMQ(N) is our expression ratio
(hereafter called T/N). If expression was undetectable in
either the normal or the tumor sample, the expression
ratio was either set to T/N = 2 (normal absent) or to T/N
= 0.5 (tumor absent). If expression was undetectable in
both the normal and tumor sample, no expression ratio
was calculated and we call the probe set not informative.
For each probe set the number of cases which showed an
up-regulation (T/N >= 2), a down-regulation (T/N <= 0.5)
Down-regulation of mRNA expression in human chromosomal region 1p36.13-1p36.11 (T/N relative expression heat map) Figure 9
Down-regulation of mRNA expression in human chromosomal region 1p36.13-1p36.11 (T/N relative expres-
sion heat map). Heat map of fold change of tumor-versus-normal expression. Genes are given in chromosomal order on the 
horizontal axis. Patient codes are given on the vertical axis. The legend depicts which colors code for which expression 
changes on a loge scale (green: down in tumor; red: up in tumor). View in conjunction with Figures 10 and 11.Molecular Cancer 2006, 5:37 http://www.molecular-cancer.com/content/5/1/37
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or the number of unchanged transcription levels (0.5 < T/
N < 2) were counted. We filtered out those probe sets
which are not informative in any patient, reducing the
number of probe sets to 19404. To eliminate redundancy
of probe sets with respect to genes, we kept only the most
informative probe set of a single gene, i.e. the probe set
which is informative in the highest number of matched
sample pairs. Additionally, only probe sets that could
unambiguously be linked to a particular genomic locus
were considered (chromosome band and position; see
Down-regulation of mRNA expression in human chromosomal region 1p36.13-1p36.11 (patient counts with coordinate up- regulation) Figure 10
Down-regulation of mRNA expression in human chromosomal region 1p36.13-1p36.11 (patient counts with 
coordinate up-regulation). Grayscale plot of cross-comparison of up-regulation patterns across patients for gene pairs in a 
particular region. Both, horizontal and vertical axes comprise the same genes in chromosomal order. In each square total 
counts of patients with consistent up-regulation in two genes are coded by different shades of gray. Dark squared regions along 
the diagonal indicate coordinated regulation in patient subgroups. View this plot in conjunction with Figures 9 and 11.Molecular Cancer 2006, 5:37 http://www.molecular-cancer.com/content/5/1/37
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Affymetrix U133A/B annotation files). Finally, the pre-
processing resulted in a total number of 10.935 probe sets
which were the basis of all further analyses.
Analysis of expression along chromosomes
In each graph of Figures 2, 3, 4, 5, we plotted the numbers
of patient samples with tumor up/down regulation (per-
Down-regulation of mRNA expression in human chromosomal region 1p36.13-1p36.11 (patient counts with coordinate down- regulation) Figure 11
Down-regulation of mRNA expression in human chromosomal region 1p36.13-1p36.11 (patient counts with 
coordinate down-regulation). Grayscale plot of cross-comparison of down-regulation patterns across patients for gene 
pairs in a particular region. Both, horizontal and vertical axes comprise the same genes in chromosomal order. In each square 
total counts of patients with consistent down-regulation in two genes are coded by different shades of gray. Dark squared 
regions along the diagonal indicate coordinated regulation in patient subgroups. Note, that many more patients show down-
regulation as indicated by dark spots in this plot than up-regulation as indicated by dark spots in Figure 10. This region has been 
reported in other studies to be frequently deleted in colorectal cancer (see Table 4). This is the most significantly down-regu-
lated region of our analysis. Note the expression of potential tumor genes PLA2G2A, E2F2, and CDC42.Molecular Cancer 2006, 5:37 http://www.molecular-cancer.com/content/5/1/37
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Down-regulation of mRNA expression in human chromosomal region 4p15.31-15.2 (T/N relative expression heat map) Figure 21
Down-regulation of mRNA expression in human chromosomal region 4p15.31-15.2 (T/N relative expression 
heat map). Heat map of fold change of tumor-versus-normal expression. Genes are given in chromosomal order on the hor-
izontal axis. Patient codes are given on the vertical axis. The legend depicts which colors code for which expression changes on 
a loge scale (green: down in tumor; red: up in tumor). View in conjunction with Figures 22 and 23.Molecular Cancer 2006, 5:37 http://www.molecular-cancer.com/content/5/1/37
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centage on informative cases) for all genes according to
their position on the chromosome. In these plots, the
smoothing of the curve is achieved by averaging over 50
consecutive genes.
Significant deviations from average expression in a partic-
ular chromosomal region is not sufficient to infer coordi-
nated deregulation. This is because it does not allow to
infer whether all genes of a region are actually de-regu-
lated in the same subset of patients. They could also be de-
regulated in different patients. Consider three genes G1,
G2, G3 and their expression in patients A,B,C,D. Each
gene is up-regulated in 50% of patients. If the genes are
up-regulated in different patients (G1 is up-regulated in
A/B, G2 is up-regulated in B/C, G3 is up-regulated in C/
D), then one can not assume that there is a regional up-
regulation in all patients. However, if the genes are up-reg-
ulated in the same patients (G1, G2 and G3 are all up-reg-
ulated in A and B), then it is fair to assume that they have
undergone coordinated regional up-regulation. Chance
Down-regulation of mRNA expression in human chromosomal region 4p15.31-15.2 (patient counts with coordinate up-regula- tion) Figure 22
Down-regulation of mRNA expression in human chromosomal region 4p15.31-15.2 (patient counts with coor-
dinate up-regulation). Grayscale cross-comparison plot of up-regulation patterns across patients (analogous to Figures 7, 
10, 13). View this plot in conjunction with Figures 21 and 23.Molecular Cancer 2006, 5:37 http://www.molecular-cancer.com/content/5/1/37
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effects more likely create non-coordinated up-regulation.
To capture such a gene-versus-gene correlation structure,
we performed the following for a given chromosome
region:
For each pair of genes of a given chromosome region we
count the number of their coordinated (simultaneous)
up-regulations (based on the above computed fold
changes) over the set of patients and the number of coor-
dinated down-regulations, separately. These values can be
represented in gray-scale plots: one gray scale plot for the
Down-regulation of mRNA expression in human chromosomal region 4p15.31-15.2 (patient counts with coordinate down-reg- ulation) Figure 23
Down-regulation of mRNA expression in human chromosomal region 4p15.31-15.2 (patient counts with coor-
dinate down-regulation). Grayscale cross-comparison plot of down-regulation patterns across patients (analogous to Fig-
ures 8, 11, 14). View this plot in conjunction with Figures 21 and 22. Note, that many more patients show down-regulation as 
indicated by dark spots in this plot than up-regulation as indicated by dark spots in Figure 22. This region has been reported in 
other studies to be frequently deleted in colon cancer (see Table 4). Note the expression down-regulation of SLIT2, GPR125 
and PCDH7.Molecular Cancer 2006, 5:37 http://www.molecular-cancer.com/content/5/1/37
Page 33 of 44
(page number not for citation purposes)
Down-regulation of mRNA expression in human chromosomal region 18q21.2-18q23 – the BCL2 region (T/N relative expres- sion heat map) Figure 24
Down-regulation of mRNA expression in human chromosomal region 18q21.2-18q23 – the BCL2 region (T/N 
relative expression heat map). Heat map of fold change of tumor-versus-normal expression. Genes are given in chromo-
somal order on the horizontal axis. Patient codes are given on the vertical axis. The legend depicts which colors code for 
which expression changes on a loge scale (green: down in tumor; red: up in tumor). View in conjunction with Figures 25 and 26.Molecular Cancer 2006, 5:37 http://www.molecular-cancer.com/content/5/1/37
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coordinated up-regulation and a similar one for coordi-
nated down-regulation. Both, horizontal and vertical axis
comprise genes of the chromosome region in the right
chromosomal order (see Figures 6, 7, 8, 9, 10, 11, 12, 13,
14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28,
29, 30, 31, 32). The darkness of squares represents the
number of coordinated up- or down-regulations, respec-
tively. Coordinately up-regulated regions show up as
squares with high "correlation" measures along the diag-
onal. Such resulting cross-comparison matrices can be vis-
ualized interactively for any chromosomal region on our
supplementary website[41] along with heat maps of
expression intensities and are used in Figures 6, 7, 8, 9, 10,
11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,
26, 27, 28, 29, 30, 31, 32. Alternatively, we applied "cor-
relation" measures like Pearson correlation coefficients on
fold changes, mutual information, and set-theoretic coef-
ficients like the Dice and Jaccard coefficients on binary
Down-regulation of mRNA expression in human chromosomal region 18q21.2-18q23 – the BCL2 region (patient counts with  coordinate up-regulation) Figure 25
Down-regulation of mRNA expression in human chromosomal region 18q21.2-18q23 – the BCL2 region 
(patient counts with coordinate up-regulation). Grayscale cross-comparison plot of up-regulation patterns across 
patients (analogous to Figures 7, 10, 13). View this plot in conjunction with Figures 24 and 26.Molecular Cancer 2006, 5:37 http://www.molecular-cancer.com/content/5/1/37
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patterns of up-regulation and down-regulation (only
available on our website [41]).
Although this analysis is already instructive for the visual
identification of general up/down-regulation of a particu-
lar region, it does not allow to infer the precise boundaries
of deregulated regions. Several software packages for the
Down-regulation of mRNA expression in human chromosomal region 18q21.2-18q23 – the BCL2 region (patient counts with  coordinate down-regulation) Figure 26
Down-regulation of mRNA expression in human chromosomal region 18q21.2-18q23 – the BCL2 region 
(patient counts with coordinate down-regulation). Grayscale cross-comparison plot of down-regulation patterns across 
patients (analogous to Figures 8, 11, 14). View this plot in conjunction with Figures 24 and 25. Note, that many more patients 
show down-regulation as indicated by dark spots in this plot than up-regulation as indicated by dark spots in Figure 25. This 
region has been reported in other studies to be frequently deleted in colon cancer (see Table 4). Note the expression down-
regulation of BCL2. SMAD4 (Hs.298320) and TCF4 are only weakly down-regulated. The DCC gene is also located in this 
region between LOC51320 and MBD2 but no informative expression measures were obtained.Molecular Cancer 2006, 5:37 http://www.molecular-cancer.com/content/5/1/37
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analysis of array CGH data exist that have been
announced to also be suited for the analysis of expression
data [42-44]. In the following, we used the ChARM soft-
ware package [44]. ChARM can be used to infer intervals
of variable size with significant positive or negative signal
amplitudes in ordered data, such as log(intensity) values
in array CGH data and mRNA expression data. We applied
the ChARM algorithm on different data sets that harbor
information about the numbers of patients with coordi-
nated up- and down-regulation of expression for all genes
on human autosomes and the X chromosome. For each
chromosome six separate data sets were prepared, accord-
ing to scanning window sizes of 5, 11, 21, 31, 41, 51.
Within each window all possible gene pairs (excluding
self comparisons) were considered. For each gene pair, the
number of coordinated up-regulated (counted as +1) and
down-regulated (counted as -1) was determined. For each
window the sum of these gene pair-specific values divided
by the total number of pairs gave the cumulative misregu-
lation score (CMS). In a sliding window approach, each
gene was associated with a CMS value. CMS values for
genes at the edges of chromosomes were calculated with
reduced window sizes. The main theoretical advantage of
the use of CMS scores compared to raw up-regulation
counts or averaged expression ratios is that it captures
only information from co-regulated neighboring gene
pairs: Noise signals fluctuate across genes and may more
often lead to artificial assignment of high expression
ratios between two genes. In contrast, real signals of
regional up-/down-regulation lead to consistent changes
in the same patients for two genes. For each window size,
CMS data sets of each chromosome were subject to
ChARM analysis. ChARM determines borders of regions
with high signal amplitudes in ordered data, here regions
of expression imbalances along a chromosome, by an
expectation-maximization approach. In addition, ChARM
provides different statistical estimates to judge the signifi-
cance of expression deregulation in a particular chromo-
somal region [44]. The identified deregulated regions
were further evaluated manually using heat maps and the
above mentioned gene-versus-gene "correlation" plots
(see above, Figures 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,
18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32
and accompanying website).
Availability and requirements
Project name: Colorectal carcinoma comparative chromo-
somal gene expression analysis (CC-CCGEA) [41].
Project home page: http://ccgea.molgen.mpg.de/cgi-bin/
ccgea/ccgea.pl
Operating system(s): all
Programming language: Perl-CGI
Licence: GNU GPL
Down-regulation of mRNA expression in human chromo- somal region 5q22.2-5q23.1 – the APC region (T/N relative  expression heat map) Figure 27
Down-regulation of mRNA expression in human 
chromosomal region 5q22.2-5q23.1 – the APC region 
(T/N relative expression heat map). Heat map of fold 
change of tumor-versus-normal expression. Genes are given 
in chromosomal order on the horizontal axis. Patient codes 
are given on the vertical axis. The legend depicts which 
colors code for which expression changes on a loge scale 
(green: down in tumor; red: up in tumor). View in conjunc-
tion with Figures 28 and 29.Molecular Cancer 2006, 5:37 http://www.molecular-cancer.com/content/5/1/37
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Down-regulation of mRNA expression in human chromosomal region 5q22.2-5q23.1 – the APC region (patient counts with  coordinate up-regulation) Figure 28
Down-regulation of mRNA expression in human chromosomal region 5q22.2-5q23.1 – the APC region (patient 
counts with coordinate up-regulation). Grayscale cross-comparison plot of up-regulation patterns across patients (analo-
gous to Figures 7, 10, 13). View this plot in conjunction with Figures 27 and 29.Molecular Cancer 2006, 5:37 http://www.molecular-cancer.com/content/5/1/37
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Additional material
Additional file 1
original ChARM output on chromosomal intervals of coordinated up- or 
down-regulated expression. This files contains the full original output of 
ChARM analyses (see methods section). Annotation of probeset IDs with 
gene symbols and chromosome bands was added subsequently.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-5-37-S1.doc]
Down-regulation of mRNA expression in human chromosomal region 5q22.2-5q23.1 – the APC region (patient counts with  coordinate down-regulation) Figure 29
Down-regulation of mRNA expression in human chromosomal region 5q22.2-5q23.1 – the APC region (patient 
counts with coordinate down-regulation). Grayscale cross-comparison plot of down-regulation patterns across patients 
(analogous to Figures 8, 11, 14). View this plot in conjunction with Figures 27 and 28. Note, that many more patients show 
down-regulation as indicated by dark spots in this plot than up-regulation as indicated by dark spots in Figure 28. This region 
has been reported in other studies to be frequently deleted in colon cancer (see Table 4). APC itself is not represented in this 
plot (no valid expression measures). It is located down-stream of TIGA1 and up-stream of DP1 and DCP2. Note the sharp 
change from expression up-regulation (TIGA1) to expression down-regulation (DCP2 to DMXL1) in this interval.Molecular Cancer 2006, 5:37 http://www.molecular-cancer.com/content/5/1/37
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